Shaun G. Goodman

St. Michael's Hospital — Canada

Medicine · Health Sciences

101h-index44.8kcitations804works12.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myocardial Infarction Research(371), Antiplatelet Therapy and Cardiovascular Diseases(227), Atrial Fibrillation Management and Outcomes(162), Cardiac Imaging and Diagnostics(156), Lipoproteins and Cardiovascular Health(135)

Publications785 total

Baseline ECG Outperforms the Angiogram for Predicting Mortality in COVID-19–Associated STEMI: Insights From the NACMI Registry
Journal of the Society for Cardiovascular Angiography & Interventions·2025Open Access
Risk Stratification in Acute Coronary Syndromes
Elsevier eBooks·2025
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome
Circulation·2025
Transfusion‐related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the <scp>MINT</scp> trial
Transfusion·2025Open Access
Abstract 4360415: Small, Dense LDL-C and Conventional LDL-C Similarly Predict Cardiovascular Risk and Benefit of Alirocumab in Statin-Treated Patients With Recent Acute Coronary Syndrome
Circulation·2025
Closing the Practice Gap in Secondary Prevention After Acute Coronary Syndromes: a Provincial Implementation Pathway
Canadian Journal of Cardiology·2025· 1 citedOpen Access
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy
Arteriosclerosis Thrombosis and Vascular Biology·2025· 2 citedOpen Access
Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: A population-based cohort study
Journal of Cardiology·2025
Lipoprotein(a) Levels and Time to Cardiovascular Benefit With Alirocumab in Patients With Recent Acute Coronary Syndrome
Journal of the American College of Cardiology·2025· 2 cited
Real-world effectiveness of early revascularization in stable coronary artery disease with moderate or severe ischemia
American Heart Journal Plus Cardiology Research and Practice·2025Open Access
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
Circulation·2025· 3 cited
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Circulation·2025· 16 citedOpen Access
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Nature Reviews Cardiology·2025· 18 cited
REAL-WORLD EFFECTIVENESS OF EARLY REVASCULARIZATION IN STABLE CORONARY DISEASE WITH MODERATE-SEVERE PERFUSION DEFECTS ON SPECT-MYOCARDIAL PERFUSION IMAGING (MPI)
Journal of the American College of Cardiology·2025Open Access
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use
JAMA Cardiology·2025· 2 citedOpen Access
Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT
Circulation Heart Failure·2025· 6 cited
Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
JACC Advances·2025· 2 citedOpen Access
Prognostic Implications of Machine Learning Algorithm–Supported Diagnostic Classification of Myocardial Injury Using the Fourth Universal Definition of Myocardial Infarction
Heart Lung and Circulation·2025Open Access
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome
European Journal of Preventive Cardiology·2025· 6 citedOpen Access
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes with Alirocumab: Post-Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial
2025Open Access
page 1 of 40Next →

Frequent Co-authors

Philippe Gabríel Steg(20), Deepak L. Bhatt(15), Harvey D. White(14), Robert A. Harrington(12), Christopher B. Granger(12), Keith A.A. Fox(12), Kim A. Eagle(10), Kenneth W. Mahaffey(9), Andrzej Budaj(9), Gregory G. Schwartz(7), Michael Szarek(7), Vera Bittner(7), Rafael Díaz(7), J. Wouter Jukema(7), Robert Pordy(7), Renato D. Lópes(7), Matthew T. Roe(6), Andreas M. Zeiher(6), Robert J. Goldberg(6), Andrew T. Yan(6)